	US 11,730,802 B2
	Zika vaccines and immunogenic compositions, and methods of using the same
Jill A Livengood, Cambridge, MA (US); Hansi Dean, Cambridge, MA (US); Htay Htay Han, Cambridge, MA (US); Raman Rao, Singapore (SG); Jackie Marks, Cambridge, MA (US); Gary Dubin, Zurich (CH); Laurence De Moerlooze, Zurich (CH); Hetal Patel, Cambridge, MA (US); and Sushma Kommareddy, Cambridge, MA (US)
Assigned to Takeda Vaccines, Inc., Cambridge, MA (US)
Appl. No. 16/761,329
Filed by TAKEDA VACCINES, INC., Cambridge, MA (US)
PCT Filed Nov. 5, 2018, PCT No. PCT/US2018/059233 § 371(c)(1), (2) Date May 4, 2020, PCT Pub. No. WO2019/090238, PCT Pub. Date May 9, 2019.
Claims priority of provisional application 62/592,995, filed on Nov. 30, 2017.
Claims priority of provisional application 62/581,500, filed on Nov. 3, 2017.
Prior Publication US 2021/0177958 A1, Jun. 17, 2021
Int. Cl. A61K 39/12 (2006.01); A61K 39/00 (2006.01); A61K 39/39 (2006.01); A61K 9/00 (2006.01); C12N 7/00 (2006.01); A61P 31/14 (2006.01)

CPC A61K 39/12 (2013.01) [A61K 9/0019 (2013.01); A61K 39/39 (2013.01); A61P 31/14 (2018.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); C12N 2770/24034 (2013.01); C12N 2770/24071 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24151 (2013.01); C12N 2770/24163 (2013.01); C12N 2770/24164 (2013.01)]

67 Claims

1. A method of vaccinating against Zika virus infection in a human subject in need thereof,

the method comprising administering to the human subject a vaccine or immunogenic composition comprising a dose of from about 1 μg to about 40 μg of an antigen from a Zika virus, wherein the antigen is an inactivated whole virus as a first (prime) and a second (boost) administration, wherein administration of the vaccine or immunogenic composition induces 14 and/or 28 days after the boost administration a seroconversion rate of at least 80% in a population of at least 20 Zika virus seronegative subjects.